You can buy or sell Stemline and other stocks, options, ETFs, and crypto commission-free!
Stemline Therapeutics, Inc. Common Stock, also called Stemline, is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Read More Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Simply Wall StMar 5
If You Had Bought Stemline Therapeutics Shares Three Years Ago You’d Have Made 93%
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. For example, Stemline Therapeutics, Inc. (NASDAQ:STML) shareholders have seen the share price rise 93% over three years, well in excess of the market return (41%, not including dividends). View our latest analysis for Stemline Therapeutics We don’t think Stemline Therapeutics’s revenue of US$500,000 is enough to establish significant demand. So it seems share...
Stock Price, News, & Analysis for Stemline Therapeutics
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, c...
-$0.74 per share
-$0.92 per share